炎症性肠病的皮肤表现

中华皮肤科杂志 ›› 2017, Vol. 50 ›› Issue (9): 689-691.

炎症性肠病的皮肤表现

李锁¹,李志量¹,荆可¹,向睿宇¹,冯素英²

1. 中国医学科学院皮肤病研究所
2. 南京中国医学科学院北京协和医学院皮肤病研究所

收稿日期:2017-06-06 修回日期:2017-07-12 出版日期:2017-09-15 发布日期:2017-08-31
通讯作者: 冯素英 E-mail:fengsuying@medmail.com.cn
基金资助:
中央级公益性科研院所基本科研业务费;北京协和医学院协和青年基金（3332016107）

Skin manifestations of inflammatory bowel diseases

suo -li¹,li zhiliang²,ke ², Rui-yu XIANG¹,

Received:2017-06-06 Revised:2017-07-12 Online:2017-09-15 Published:2017-08-31
Supported by:
Central Public-interest Scientific Institution Basal Research Fund;Youth Foundation of Peking Union Medical College

摘要/Abstract

摘要： 炎症性肠病（inflammatory bowel disease，IBD）是一类病因和发病机制尚不明确的慢性非特异性肠道疾病，包括溃疡性结肠炎（ulcerative colitis）和克罗恩病（Crohn disease）。目前普遍认为，环境、基因、免疫及肠道微生态共同作用，致使遗传易感个体肠道免疫系统对肠腔内抗原，如食物代谢成分或肠道共生微生物等产生异常免疫反应［1］。高达40%的炎症性肠病患者可并发肠外表现，肠外表现的临床谱非常广泛，其表现有时甚至比IBD本身更为严重［2］。肠外表现中皮肤是常受累的器官之一，大约有22% ~ 75%的克罗恩病患者和5% ~ 11%的溃疡性结肠炎患者合并皮肤表现，并随疾病病程的延长出现比例会进一步增加［3］。炎症性肠病的皮肤表现可分为4类：①特异性皮肤表现：与炎症性肠病有相同的组织病理学改变；②反应性皮肤表现：由肠道菌群和皮肤共同抗原导致的异常免疫反应引起；③相关性皮肤表现：与炎症性肠病的特殊HLA基因表达和慢性炎症状态有关；④继发性皮肤表现：与营养素缺乏或药物诱发有关［4?5］……

李锁李志量荆可向睿宇冯素英. 炎症性肠病的皮肤表现[J]. 中华皮肤科杂志, 2017, 50(9): 689-691.

suo -li li zhiliang ke Rui-yu XIANG. Skin manifestations of inflammatory bowel diseases[J]. Chinese Journal of Dermatology, 2017, 50(9): 689-691.

参考文献 34

［1］	Holleran G, Lopetuso LR, Ianiro G, et al. Gut microbiota and inflammatory bowel disease: an update［J］. Minerva Gastroenterol Dietol, 2017. DOI: 10.23736/S1121⁃421X.17.02386⁃8.
［2］	Huang BL, Chandra S, Shih DQ. Skin manifestations of inflam⁃matory bowel disease［J］. Front Physiol, 2012, 3: 13. DOI: 10.3389/fphys.2012.00013.
［3］	Marzano AV, Borghi A, Stadnicki A, et al. Cutaneous mani⁃festations in patients with inflammatory bowel diseases: pathophysiology, clinical features, and therapy［J］. Inflamm Bowel Dis, 2014, 20（1）: 213⁃227. DOI: 10.1097/01.MIB. 0000436959.62286.f9.
［4］	Mnif L, Amouri A, Tahri N. Cutaneous manifestations of inflam⁃matory bowel disease［J］. Tunis Med, 2010, 88（6）: 420⁃423.
［5］	Passarini B, Infusino SD, Barbieri E, et al. Cutaneous manifes⁃tations in inflammatory bowel diseases: eight cases of psoriasis induced by anti⁃tumor⁃necrosis⁃factor antibody therapy［J］. Dermatology, 2007, 215（4）: 295⁃300. DOI: 10.1159/000107622.
［6］	Chavez⁃Álvarez S, Gómez⁃Flores M, Ocampo⁃Candiani J. Cutaneous manifestations in inflammatory bowel disease［J］. Gac Med Mex, 2016, 152（5）: 622⁃630.
［7］	Hsu YC, Wu TC, Lo YC, et al. Gastrointestinal complications and extraintestinal manifestations of inflammatory bowel disease in Taiwan: a population⁃based study［J］. J Chin Med Assoc, 2017, 80（2）: 56⁃62. DOI: 10.1016/j.jcma.2016.08.009.
［8］	Bouguen G, Siproudhis L, Bretagne JF, et al. Nonfistulizing perianal Crohn′s disease: clinical features, epidemiology, and treatment［J］. Inflamm Bowel Dis, 2010, 16（8）: 1431⁃1442. DOI: 10.1002/ibd.21261.
［9］	Bender⁃Heine A, Grantham JT, Zaslau S, et al. Metastatic Crohn disease: a review of dermatologic manifestations and treatment［J］. Cutis, 2017, 99（6）: E33⁃E40.
［10］	Satoh TK, Mellett M, Contassot E, et al. Are neutrophilic dermatoses autoinflammatory disorders?［J］. Br J Dermatol, 2016. DOI: 10.1111/bjd.15105.
［11］	Stingeni L, Tramontana M, Bassotti G, et al. Pyodermatitis⁃pyostomatitis vegetans and antibullous pemphigoid antigen 180 autoantibodies: a casual association?［J］. Br J Dermatol, 2015, 172（3）: 811⁃813. DOI: 10.1111/bjd.13297.
［12］	Dodd EM, Howard JR, Dulaney ED, et al. Pyodermatitis⁃pyostomatitis vegetans associated with asymptomatic inflam⁃matory bowel disease［J］. Int J Dermatol, 2017. DOI: 10.1111/ijd.13640.
［13］	Clark LG, Tolkachjov SN, Bridges AG, et al. Pyostomatitis vegetans （PSV）⁃pyodermatitis vegetans （PDV）: a clinicopatho⁃logic study of 7 cases at a tertiary referral center［J］. J Am Acad Dermatol, 2016, 75（3）: 578⁃584. DOI: 10.1016/j.jaad.2016.03. 047.
［14］	Ficarra G, Baroni G, Massi D. Pyostomatitis vegetans: cellular immune profile and of IL⁃6, IL⁃8 and TNF⁃alpha［J］. Head Neck Pathol, 2010, 4（1）: 1⁃9. DOI: 10.1007/s12105⁃009⁃0149⁃7.
［15］	Nestor LA, Tobin AM. Oral Sweet′s syndrome occurring in ulcerative colitis［J］. BMJ Case Rep, 2017, 2017. DOI: 10.1136/bcr⁃2016⁃218249.
［16］	Wells MM, Stecho W, Wehrli B, et al. Sweet syndrome secondary to inflammatory bowel disease［J］. Can J Gastroenterol, 2013, 27（3）: 124⁃125. DOI: 10.1155/2013/848316.
［17］	Cui RZ, Bruce AJ, Rogers RS. Recurrent aphthous stomatitis［J］. Clin Dermatol, 2016, 34（4）: 475⁃481. DOI: 10.1016/j.clindermatol.2016.02.020.
［18］	Edgar NR , Saleh D , Miller RA . Recurrent aphthous stomatitis: a review［J］. J Clin Aesthet Dermatol, 2017, 3（10）: 26⁃36.
［19］	Zhao H, Zhao L, Shi W, et al. Is it bowel⁃associated dermatosis⁃arthritis syndrome induced by small intestinal bacteriaovergrowth?［J］. Springerplus, 2016, 5（1）: 1551. DOI: 10.1186/s40064⁃016⁃3236⁃8.
［20］	李忱, 徐文睿, 刘晋河, 等. SAPHO综合征的临床表现和影像学评估的研究进展［J］. 医学研究杂志, 2016, 45（4）: 181⁃183. DOI: 10.11969/j.issn.1673⁃548X.2016.04.048.
［21］	Naves JE, Cabré E, Mañosa M, et al. A systematic review of SAPHO syndrome and inflammatory bowel disease association［J］. Dig Dis Sci, 2013, 58（8）: 2138⁃2147. DOI: 10.1007/s10620⁃013⁃2653⁃6.
［22］	Löffler W, Lohse P, Weihmayr T, et al. Pyogenic arthritis, pyoderma gangrenosum, and acne （PAPA） syndrome: differential diagnosis of septic arthritis by regular detection of exceedingly high synovial cell counts［J］. Infection, 2017. DOI: 10.1007/s15010⁃017⁃0996⁃1.
［23］	Lindwall E, Singla S, Davis WE, et al. Novel PSTPIP1 gene mutation in a patient with pyogenic arthritis, pyoderma gangre⁃nosum and acne （PAPA） syndrome［J］. Semin Arthritis Rheum, 2015, 45（1）: 91⁃93. DOI: 10.1016/j.semarthrit.2015.02. 012.
［24］	Zouboulis CC. Acne as a chronic systemic disease［J］. Clin Dermatol, 2014, 32（3）: 389⁃396. DOI: 10.1016/j.clindermatol. 2013.11.005.
［25］	Hindryckx P, Novak G, Costanzo A, et al. Disease⁃related and drug⁃induced skin manifestations in inflammatory bowel disease［J］. Expert Rev Gastroenterol Hepatol, 2017, 11（3）: 203⁃214. DOI: 10.1080/17474124.2017.1283985.
［26］	Farhi D, Cosnes J, Zizi N, et al. Significance of erythema nodosum and pyoderma gangrenosum in inflammatory bowel diseases: a cohort study of 2402 patients［J］. Medicine （Baltimore）, 2008, 87（5）: 281⁃293. DOI: 10.1097/MD.0b013e318187cc9c.
［27］	Ampuero J, Rojas⁃Feria M, Castro⁃Fernández M, et al. Predictive factors for erythema nodosum and pyoderma gangrenosum in inflammatory bowel disease［J］. J Gastroenterol Hepatol, 2014, 29（2）: 291⁃295. DOI: 10.1111/jgh.12352.
［28］	Pescitelli L, Gianotta M, Ricceri F, et al. Clinical characteristics of psoriasis in inflammatory bowel disease patients［J］. J Eur Acad Dermatol Venereol, 2017. DOI: 10.1111/jdv.14230.
［29］	Skroza N, Proietti I, Pampena R, et al. Correlations between psoriasis and inflammatory bowel diseases［J］. Biomed Res Int, 2013, 2013: 983902. DOI: 10.1155/2013/983902.
［30］	Fogel O, Richard⁃Miceli C, Tost J. Epigenetic changes in chronic inflammatory diseases［J］. Adv Protein Chem Struct Biol, 2017, 106: 139⁃189. DOI: 10.1016/bs.apcsb.2016.09.003.
［31］	Binus AM, Han J, Qamar AA, et al. Associated comorbidities in psoriasis and inflammatory bowel disease［J］. J Eur Acad Dermatol Venereol, 2012, 26（5）: 644⁃650. DOI: 10.1111/j.1468⁃3083.2011.04153.x.
［32］	Hohenberger M, Cardwell LA, Oussedik E, et al. Interleukin⁃17 inhibition: role in psoriasis and inflammatory bowel disease［J］. J Dermatolog Treat, 2017: 1⁃6. DOI: 10.1080/09546634.2017. 1329511.
［33］	Puig L. The role of IL 23 in the treatment of psoriasis［J］. Expert Rev Clin Immunol, 2017, 13（6）: 525⁃534. DOI: 10.1080/1744666X.2017.1292137.
［34］	Reddy H, Shipman AR, Wojnarowska F. Epidermolysis bullosa acquisita and inflammatory bowel disease: a review of the literature［J］. Clin Exp Dermatol, 2013, 38（3）: 225⁃229; quiz 229⁃230. DOI: 10.1111/ced.12114.